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Objective To describe the incidence and clinical characteristics of mycobacterial infec-
tion in renal transplant recipients.
Methods We retrospectively analyzed the cases of mycobacterial infection in a series of
1261 renal transplants carried out in our Unit of Renal Transplantation from 1980 to 2000.
Demographic parameters and clinical antecedents such as age, cause of end-stage renal
disease, time of follow-up of the graft, previous renal function and type of immuno-
suppression were considered. Moreover, the clinical onset, diagnostic tools, treatment
policy and evolution were studied. The pathogenesis of the different types of myco-
bacteria isolated was also analyzed. Diagnosis was made with the Ziehl–Neelsen staining
method. Culture was performed by the conventional Lo¨wenstein–Jensen method and the
Bactec-460 radiometric method.
Results We found mycobacterial infection in 27 patients (2.1%), due to Mycobacterium
tuberculosis in 20 cases, M. kansasii in five patients, and M. fortuitum in two patients. The
mean elapsed time from the renal transplant was 20.5 months; the infection appeared in
18 patients during the first eight months after transplantation. The clinical onset was
pulmonary infection in 17 cases (12 M. tuberculosis and five M. kansasii); five had urinary
symptoms (three M. tuberculosis and two M. fortuitum); three cases of M. tuberculosis
infection had abdominal symptoms; another one began with a perineal tuberculous
abscess; the rest of the patients were asymptomatic. The types of specimen on which
microbiological identification was carried out were, in decreasing order: sputum and/or
bronchial washing/pleural aspiration, urine, feces, gastric and peritoneal fluids, bone
marrow and blood. The first-line drug isoniazid had the highest resistance index in the
susceptibility test. Clinical dissemination was observed in eight patients, four of whom
died. Another three patients had a significant impairment in renal function, and in one of
these patients an allograft nephrectomy was necessary due to a severe septic syndrome.
Conclusions Mycobacterial infection, mainly by M. tuberculosis, has an important impact
on kidney transplant recipients, particularly during the first year after surgery. Diagnosis
often presents some difficulties, and a delay in treatment represents a determinant factor
for the evolution, with a risk of death or permanent damage in renal function. Therefore,
early diagnosis is mandatory. When the Mantoux reaction is positive, antituberculous
prophylaxis seems advisable.
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O B J E C T I V E
Infection by mycobacteria in kidney transplant
recipients is not rare, Mycobacterium tuberculosis
being the most frequently isolated pathogen in
our geographic area. The other mycobacteria
(non-tuberculous mycobacteria) that cause infec-
tion, M. kansasii, M. chelonae, M. fortuitum, M.
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marinum and the M. avium complex, have a lower
incidence. Kidney transplant recipients have a
higher incidence of mycobacterial infection than
the general population, due to cellular immuno-
suppression. In our environment, with a high
prevalence of tuberculosis, it is very important
to address this problem.
We retrospectively analyzed the impact of
mycobacterial infection both on the renal graft
and on the patient in a series of 1261 kidney
transplants carried out in our unit over the last
20 years.
M E T H O D S
This was a retrospective study analyzing those
cases of infection caused by mycobacteria in our
Unit of Renal Transplantation from 1980 to 2000.
The study included 1261 renal grafts. The etiology
of the end-stage renal disease (ESRD) in this group
of kidney transplant recipients was mainly glo-
merulonephritis (13 cases), followed by interstitial
pathology (11 cases), and polycystic renal disease
(three cases). The mean time spent in the hemodia-
lysis program was 35.9 months (25–60 months).
The source of the graft, in the vast majority of
cases (98.8%), comprised brain-dead heart-beating
cadavers. In the rest of the cases, the graft came
from living related donors.
The immunosuppressive drugs used were
prednisone, cyclosporin A, azathioprine, myco-
phenolate mofetil, and tacrolimus. The immuno-
suppressive regimen combined two or three
drugs, and was modified according to the graft
evolution and appearance of toxicity (renal func-
tion impairment). Initially, the prednisone dose
was 30 mg/day; this was reduced fortnightly,
to reach a maintenance dose of 10 mg/day in
the sixth month. The dose of cyclosporin A was
7 mg/kg per day, with variations according to
blood levels (between 100 and 150 ng/mL). The
dose of azathioprine was 1.5 mg/day, with a gra-
dual reduction such that the treatment could be
stopped in the third month. In the final two years,
cyclosporin A was replaced by tacrolimus
(0.1 mg/kg/day), and azathioprine by mycophe-
nolate mofetil (1.5–2 g/day). During post-trans-
plant follow-up, periodic surveillance cultures
for mycobacteria were done at three, six and
12 months, and yearly thereafter.
The time between the kidney transplant and
infection was analyzed, and so were the different
clinical manifestations related to the affected organ
and the presence of dissemination of infection.
Diagnosis was made with the Ziehl–Neelsen
stain method. Culture was performed with the
conventional Lo¨wenstein–Jensen method and the
Bactec-460 radiometric method (Johnson Laborat-
orie Towson, Baltimore, MO, USA; Becton-Dick-
inson, Madrid, Spain).
Microbiological identification was carried out
by conventional methods (time of growth, mor-
phology and stain pattern of the colony (pigmen-
tation of the colony), niacin production, nitrate
reduction, detection of catalase, etc). Sensitivities
to the traditional antituberculous drugs were
tested (isoniazid, rifampicin, ethambutol, strepto-
mycin, and pyrazinamide), and, with the help of
the multiple ratio method, the sensitivities of sec-
ond-line antituberculous drugs were also studied
(para-aminosalicylate, kanamycin, capreomycin,
cycloserine, and ethionamide). In some cases,
the microbiological diagnosis was complemented
with the pathoanatomic study of biopsy samples,
where specific tuberculous granulomata were
identified.
The treatment, its effectiveness, its side-effects
and its pharmacologic interactions were also
recorded. Finally, the evolution of the infectious
process, and its effects on the graft and on the
patient generally, and the patient’s survival rate
concluded the study.
R E S U L T S
Infection by mycobacteria developed in 27 (2.3%)
of the 1261 renal transplant recipients. Twenty
patients (74%) were infected with M. tuberculosis,
five (19%) with M. kansasii, and two (7%) with M.
fortuitum. The mean age of this group of patients
was 43.9 years (range 21–62), and men predomi-
nated (17/27 cases). The main characteristics of the
patients are described in Tables 1 and 2.
The mean duration of previous hemodialysis
was 35.9 months (range 25–60). The causes of
ESRD were glomerulonephritis in 13 (48%) cases,
interstitial nephropathy in 11 (41%) cases, and
polycystic renal disease in three (11%) cases.
Twenty patients (74%) showed good graft
function (creatinine (Cr) <2 mg/dL, and urea
<100 mg/dL). The other seven patients (26%)
developed moderate renal failure (Cr levels
between 2 and 5 mg/dL, and urea levels between
100 and 200 mg/dL).
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Table 1 Main characteristics of patients infected by M. tuberculosis
Patient
no. Sex
Age
(years)
Time
after
transplant
(months)
Tuberculin
test
Previous
tuberculosis
Radiologic
alteration
Type of
disease
Specimen on which
identification was
carried out Outcome
1 Male 48 7 Positive No No Pulmonary Sputum Cured
2 Female 49 9 Negative No No Pulmonary Sputum Cured
3 Male 45 4 Positive Yes Yes Pulmonary Bronchial washing,
pleural effusion
Disseminated.
Died
4 Male 36 114 Negative No No Urinary Urine Cured
5 Female 32 2 Positive Yes Yes Pulmonary Bronchial washing Disseminated.
Cured
6 Female 37 56 Negative No No Asymptomatic Urine Cured
7 Male 21 10 Positive No No Intestinal Feces,
gastric aspirate
Disseminated.
Cured
8 Female 46 15 Negative No No Pulmonary Bronchial washing Cured
9 Male 33 5 Positive No No Pulmonary Sputum,
bronchial washing
Disseminated.
Cured
10 Male 38 39 Negative No No Urinary Urine Cured
11 Male 55 7 Positive No No Pulmonary Sputum Cured
12 Male 43 6 Positive Yes Yes Intestinal Blood,
gastric aspirate,
feces, BMA, PA
Disseminated.
Died
13 Female 34 71 Negative No No Skin abscess Abscess aspirate Cured
14 Female 36 40 Negative No No Pulmonary Bronchial washing Cured
15 Male 32 8 Negative No No Urinary Urine Cured
16 Female 38 12 Negative No No Pulmonary Bronchial washing Cured
17 Male 39 35 Positive No No Intestinal Gastric aspirate,
feces
Disseminated.
Died
18 Male 45 6 Negative No No Pulmonary Bronchial washing Cured
19 Female 34 44 Positive No No Pulmonary Sputum, feces Disseminated.
Cured
20 Male 50 28 Negative No No Pulmonary Sputum Cured
PA, peritoneal aspirate; BMA, bone marrow aspirate.
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The mean elapsed time from the renal graft to
the infectious process was 20.5 months (range: 2–
114). However, infections appeared in 18 (67%)
cases during the first eight post-transplantation
months. The most frequent initial clinical manifes-
tations were: pleuropulmonary in 17 cases (63%),
urinary in five cases (19%), intestinal in three cases
(11%), and a perineal tuberculous abscess in one
case (4%); the remaining case was asymptomatic
(4%).
M. tuberculosis was isolated in 12 cases with
pleuropulmonary manifestations, and M. kansasii
in five patients. Intestinal manifestations were due
to M. tuberculosis in all cases. Urinary infection was
caused by M. tuberculosis in three cases and by M.
fortuitum in two cases. Therefore, M. kansasii
always produced respiratory infection, whereas
M. fortuitum was always responsible for urinary
infection.
Eight patients (30%) underwent clinically evi-
dent dissemination; seven cases involved M. tuber-
culosis, and one case M. kansasii.
Infection with Mycobacterium tuberculosis
In total, 12 men and eight women had M. tuber-
culosis infections (1.6%). The mean ages were
40.4 and 38.3 years, respectively (range: 21–55).
The mean time of immunosuppression was
25.9 months, but 11 of the 20 cases appeared dur-
ing the first year after the graft. The renal function
previous to the infectious process was normal in 16
of 20 (80%) patients.
Pulmonary manifestations
Twelve of 20 cases (60%) showed respiratory pro-
blems, the main symptoms being fever, cough,
expectoration, pleuritic pain, and non-specific
symptoms (weight loss or night sweats). The chest
radiograph showed non-segmental consolidation
in all cases, with a miliary pattern in four and
pleural effusion in three. Dissemination of infec-
tion occurred in four of the 12 cases; one of them
required allograft nephrectomy (since the graft
was established as the septic focus), another died,
and, in a third, renal function was permanently
impaired.
Intestinal manifestations
Three (15%) patients presented with abdominal
pain, fever and constitutional symptoms: there
was dissemination of infection in all three. One
of them had an intestinal perforation that required
urgent surgical treatment (intestinal resection).
The other two died, one of them after a severe
intestinal hemorrhage secondary to a tuberculous
duodenal ulcer, and the other as a direct conse-
quence of a septic syndrome complicated by multi-
ple antimicrobial resistance.
Other clinical manifestations
Three (15%) patients had irritative urinary symp-
toms and fever; another one developed a perineal
tuberculous abscess, and his condition improved
after surgical drainage; the remainder of the
patients with infection were completely asympto-
matic.
Infection with Mycobacterium kansasii
In total, three men and two women had M. kansasii
infections (18.5%). The mean age was 49.8 years
(range: 31–62). The time of immunosuppression
was 5.6 months (range: 2–7). All patients had
pulmonary manifestations with fever and foci of
pneumonic consolidation; one patient died of
acute respiratory failure due to massive dissemi-
nation.
Table 2 Main characteristics of patients infected by M. kansaii and M. fortuitum
Patient
no. Sex
Age
(years)
Time after
transplant
Mycobacterial
species
Type of
disease
Place of
identification Outcome
21 Male 62 7 M. kansasii Pulmonary Sputum, bronchial washing Cured
22 Female 47 6 M. kansasii Pulmonary Sputum Cured
23 Male 31 6 M. kansasii Pulmonary Bronchial washing,
pleural effusion
Disseminated.
Died
24 Male 51 7 M. kansasii Pulmonary Sputum Cured
25 Female 58 2 M. kansasii Pulmonary Bronchial washing Cured
26 Male 50 2 M. fortuitum Urinary Urine Cured
27 Male 55 6 M. fortuitum Urinary Urine Cured
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Infection with Mycobacterium fortuitum
The two cases were men (50 and 55 years old), and
the infection appeared after two and six months
of immunosuppression, respectively. The clinical
onset comprised micturitional symptoms and
fever, and the urinalysis showed the presence of
sterile pyuria. The evolution after treatment was,
in both patients, excellent.
Elapsed time from graft transplantantion to
clinical onset was different depending on the
microorganism involved (Table 2).
Microbiological parameters
The specimen for the microbiological identifica-
tion depended on the organs involved and the
presence or absence of dissemination. In those
patients with pleuropulmonary manifestations,
the bacillus was identified from sputum and bron-
chial washings or from the pleural fluid. In
patients with urinary symptoms, the microorgan-
ism was isolated from urine. When an infectious
disseminated process was suspected, samples were
collected from multiple locations; consequently,
in the three cases of intestinal tuberculosis, the
mycobacterium was present in pleuropulmonary
secretions, urine, and feces. Furthermore, in patho-
anatomic studies, granulomata were identified in
biopsy samples of lung, peritoneum, ileal wall,
and laryngeal mucus.
In 18 patients, the pattern of resistance to
antituberculous drugs was analyzed, always
including isoniazid, rifampicin, ethambutol,
streptomycin, and pyrazinamide, among others.
One isolate of M. tuberculosis was resistant to iso-
niazid, rifampicin and streptomycin, and the
patient was treated with ethambutol, pyrazina-
mide, and the second-line drug para-aminosa-
licylic acid. On the other hand, M. kansasii was
often resistant to isoniazid (four of five cases), and
M. fortuitum was resistant to the four drugs
(Table 3).
Treatment
The first-line antituberculous drugs were isonia-
zid, rifampicin, and ethambutol. Streptomycin and
pyrazinamide were used as a fourth drug or as a
substitute for ethambutol. Doses were those
recommended: isoniazid 300 mg/day, rifampicin
600 mg/day, and ethambutol depending on the
renal function. Changes in immunosuppressive
drugs were made according to levels and varia-
tions of antituberculous drugs (according to the
levels of immunosuppressive and antituberculous
drugs used). As secondary effects attributed to
these drugs, we must emphasize effects on the
liver, marked by mild and temporary elevations
in the levels of transaminases in three cases. In one
case, ethambutol caused skin desquamation asso-
ciated with urticaria and deterioration of renal
function. Rifampicin and cyclosporin A are meta-
bolized by the same cytochrome (P-450), so it was
necessary to increase the cyclosporin A dose or, in
some other cases, to replace the rifampicin with
pyrazinamide. In four cases, it was necessary to
increase the doses of cyclosporin, and in three
cases, to substitute rifampicin for pyrazinamide.
The duration of treatment was at least 9 months,
but among the cases of miliary tuberculosis or
disseminated infection, a longer duration and
the use of a fourth drug was necessary in eight
cases. When the infection was due to atypical
mycobacteria, our choice of treatment was strictly
based on the antibiogram in order to avoid the
foreseeable high index of antimicrobial resistance.
Therefore, for M. kansasii, isoniazid was replaced
by ciprofloxacin, and for M. fortuitum, treatment
was with aminoglycosides, amoxicillin–clavulanic
acid, and cephalosporins.
Evolution
There was significant impairment of renal func-
tion in three patients (11%). Allograft nephrec-
tomy was needed in one of these cases (due to
Number susceptible to
Isoniazid Rifampicin Ethambutol Streptomycin
Mt (11) 10 10 11 10
Mk (5) 0 5 5 5
Mf (2) 0 0 0 0
Mt, M. tuberculosis; Mk, M. kansasii; Mf, M. fortuitum.
Table 3 Antimicrobial sensitivity
(available in only 18 cases)
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infectious dissemination by M. tuberculosis with
graft infection). In the rest of the cases, there was a
mild deterioration of renal function but later
recovery.
The mean follow-up was 54.4 months (range:
7–122). In one patient, a clinical recurrence after
three months of treatment was detected, requiring
a change of the antituberculous drugs and the use
of a fourth drug.
D I S C U S S I O N
The pathogenic nature of the mycobacteria, apart
from M. tuberculosis, is not well known. Infection
by mycobacteria usually appears in immuno-
compromised subjects and with a typical onset
of pulmonary manifestations. However, mycobac-
teria sometimes cause lymphadenitis, cutaneous
and osteoarticular infections, and, less frequently,
infection of the genitourinary tract and of the
central nervous system (meningitis). Dissemina-
tion is not a frequent event. Diagnosis is often
difficult, because the patients are immunocompro-
mised, and consequently they show atypical man-
ifestations [1].
In our series, M. tuberculosis presented with
serious intestinal manifestations in three cases,
and with a subcutaneous abscess in another case.
M. kansasii showed pulmonary manifestations
similar to tuberculosis. Dissemination appeared
in only one case, but with lethal consequences.
M. fortuitum was responsible for two urinary infec-
tions of less importance.
Mycobacterium tuberculosis
The incidence of tuberculosis in kidney transplant
recipients varies according to the prevalence in the
general population, and is higher in areas such as
India or South Africa, where this disease is ende-
mic. In several series, prevalences of 0.35–1.2% in
the USA, 0.7–5% in Europe and 5–15% in South
Africa and India have been described; these pre-
valences are up to 100 times higher than those in
the general populations of these countries [2–8]. In
our series, the incidence was 1.6%, which is
slightly higher than previously reported in Spain
by Aguado et al. [9]. Prophylaxis with isoniazid
(300 mg/day) and pyridoxine (25 mg/day) is not
routinely carried out, since these drugs are toxic
and the resistance levels to isoniazid are increas-
ing. In our unit, prophylaxis with isoniazid (for
9 months) is carried out in patients with radiologic
features compatible with old pulmonary infection
or a positive Mantoux reaction (a purified protein
derivative (PPD) skin test was performed as soon
as the patient was included in the waiting list for a
cadaveric transplant), as long as active tuberculo-
sis is ruled out (by means of a sputum study with
Ziehl–Neelsen stain and Lowenstein culture), and
provided that there are no contraindications to
isoniazid administration (previous hepatitis due
to isoniazid and acute hepatic disease). Follow-up
includes mycobacterial cultures. According to
Singh and Paterson [6] and Qunibi et al. [7], the
indications for prophylaxis with isoniazid for a
year are: tuberculin test >5–10 mm before the
transplant without previous treatment; evidence
of an old tuberculous untreated lesion on chest
X-ray; a history of inappropriate tuberculosis treat-
ment; contact with patients with active disease;
and an incorrectly treated donor with a medical
history of tuberculosis or a positive tuberculin test
without adequate prophylaxis. In the series of
Higgins et al. [4] (11 cases of mycobacterial infec-
tion out of 633 renal transplants), there were no
cases of tuberculous infection among the patients
who received prophylaxis. However, among those
patients without prophylaxis (in spite of a higher
risk as a result of being in an endemic area), a
tuberculous infection developed in 22% (six of 27
patients). Riska et al. [8] stated that prophylaxis
with isoniazid was not indicated for those patients
whose tuberculosis had been properly treated.
Clinical experience shows that isoniazid alone is
effective as prophylaxis but is not completely
protective.
The number of patients reported in the majority
of published series is less than 10, and so our series
is one of the largest reported. The clinical onset in
other series usually occurred before the end of the
first year after transplantation [7], and patients
with a positive tuberculin test developed tubercu-
losis earlier [6]. In our series, the average time of
presentation was 25.9 months, but infection
appeared in 11 patients during the first 12 months
after transplantation. The mean age of our patients
was 39.6 years, which is very close to that reported
by Qunibi et al. [7], where 71% of patients were
under 40 years old.
Activation of latent tuberculosis in a context of
immunodeficiency is more likely to disseminate,
becoming worse if the patient also presents other
immunodeficiency factors, such as uremia [7].
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Infection from contaminated donors is also possi-
ble [10,11]. On the other hand, contamination from
bronchoscopes or endotracheal intubation has also
been reported [12].
Fever is the most common symptom, together
with anorexia and night sweats. Specific clinical
manifestations vary depending on the affected
organ. In pulmonary infection, expectoration
and pleuritic pain are very common; the most
frequent radiologic patterns are focal infiltration
and a miliary pattern. In our series, fever was
recurrent, and miliary dissemination was found
in four cases. In one such case, an allograft
nephrectomy was required, owing to septic pro-
blems associated with severe renal failure.
Intestinal infection is the most frequent extra-
pulmonary manifestation. Abdominal pain and
intestinal bleeding are the most common clinical
features [6]. In our series, dissemination occurred
in three cases, with subsequent massive hemor-
rhage and intestinal perforation in two of them.
The third patient died because of dissemination
and resistance to the first-line antituberculous
drugs.
Urinary tuberculosis is relatively uncommon,
with an incidence of 7.1–11% in the most important
series [6,7]. In our study, it accounted for 15% of
cases. Other areas less often affected are skin,
muscle, and the osteoarticular system. Tubercu-
lous meningitis and brain abscess appear in the
context of dissemination. In our series, a patient
presented with a perineal abscess; tuberculous
granulomas were identified in another patient
through a larynx biopsy, and a third case pre-
sented with a tuberculous subcutaneous abscess.
Tuberculous dissemination occurs in 40–64% of
cases [6,7] versus 0.6–1.4% in the general popula-
tion [13]. In our series, dissemination occurred in
35% of cases. The most frequent clinical features
are fever, cough, abdominal pain, dyspnea, and
fatigability, and the mortality rate is about 37%.
The type of immunosuppression seems to play an
important role, since several authors report a
higher dissemination risk if OKT3 anti-cell (anti-
CD3 monoclonal antibody) is used [6,14]. John et al.
[15] did not find differences in the incidence of
dissemination between patients treated with
cyclosporin and those treated with conventional
immunosuppression.
In the general population, the most common
antituberculous therapy has comprised isoniazid
and rifampicin for at least six to nine months, with
a third drug during the first two months. Riska
et al. [8] advised a similar treatment for renal
transplant patients for nine months, although
longer treatments have also been recommended
[2,7,16]. When pyrazinamide is substituted by
other drugs, the treatment should be extended
(12–18 months) [6]. The most serious drawback
associated with antituberculous treatment is
the severe rejection due to interaction between
rifampicin and cyclosporin. In such cases, an
immunosuppressive dose adjustment or rifampi-
cin substitution is required [17].
Isoniazid-related hepatotoxicity appears in 9%
of patients between the first and the sixth week of
treatment [6,18].
There is a direct relationship between renal
function impairment and mortality. In our series,
three (15%) patients died and another two had
serious renal function impairment. In another
patient, allograft nephrectomy was required.
The most important risk factors are the type of
clinical onset and the presence of dissemination.
Graft rejection and OKT3 or anti-T-cell antibodies
are also important. Age, time from the graft and
hepatotoxicity are not described as predictors of a
poor prognosis [6].
Non-tuberculous mycobacteria (Mycobacterium
kansasii and Mycobacterium fortuitum)
The transmission of these opportunists is usually
aerial, but direct inoculation in soft tissues due to
surgery is also possible [1]. Up to 43% of infections
by mycobacteria in renal transplant recipients are
due to atypical mycobacteria, the most usual
microorganism (75% of cases) being M. kansasii [7].
In a worldwide review by Patel et al. [19], the
most frequent clinical manifestations were skin
abscess, lesions in the osteoarticular system and
pulmonary symptoms. There are ten described
cases caused by M. fortuitum whose main clinical
manifestation was granulomatosis that required
surgical debridement. These lesions were located
in the arms and lower limbs.
In our series, a patient with massive dissemina-
tion of M. kansasii from a pulmonary focus died.
The two cases of infection by M. fortuitum could
have been caused by urologic manipulation. Infec-
tions by atypical mycobacteria appeared in all our
cases during the first year after transplantation
(with mean times of four months for M. fortuitum
and 5.6 months for M. kansasii).
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Dissemination is not a frequent event [19], but if
present, has lethal consequences unless it is treated
early [20]. The atypical mycobacteria except M.
kansasii and M. marinum are often resistant to
antituberculous drugs [21]. This should be taken
into account before the start of treatment, and a
previous antibiogram is advisable. Infection by M.
fortuitum requires different drugs, the most usual
being amikacin, cephalosporins, doxycycline, ery-
thromycin, and quinolones [20].
C O N C L U S I O N S
There is a high incidence of infection by mycobac-
teria in renal transplant recipients, especially dur-
ing the first year after transplantation, M.
tuberculosis being the most frequent microorgan-
ism involved in our geographic area. Non-tuber-
culous mycobacteria have a much smaller impact
on such patients. An early diagnosis is still crucial,
because any delay in treatment is a determining
factor for the evolution of the renal graft and
represents an increased mortality risk. Taking into
account the high levels of antimicrobial resistance,
an antibiogram is a sensible guide to treatment.
Finally, in areas of high prevalence of tuberculosis,
chemoprophylaxis is recommended in patients
with positive Mantoux tests.
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